At equivalent diabetes doses, the two medications produce very similar GI side effect rates
(2007) 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes
It is the customer's responsibility to verify whether the products are permitted to enter their country
Conditions like Crohns disease, celiac disease, or low stomach acid can interfere with the bodys ability to absorb B12 effectively
Other tentative factors are strain of rats and route of administration
**%Daily Value based on 2,000 calorie diet